This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Institute For Systems Biology Places A Third Order For Sequencing Services With Complete Genomics, Includes 615 Genomes

MOUNTAIN VIEW, Calif., Jan. 11, 2011 (GLOBE NEWSWIRE) -- The Institute for Systems Biology (ISB) and Complete Genomics Inc. (Nasdaq:GNOM) announced today the signing of an agreement that calls for Complete Genomics to sequence 615 complete human genome samples as part of an ISB study on neurodegenerative diseases.

In 2009, ISB engaged Complete Genomics to sequence four genomes as part of a small family study to verify the causal gene in Miller syndrome. This initial project resulted in a publication in Science 1 that also documented the low error rates in the data generated by Complete Genomics.

More recently, in early 2010, ISB engaged Complete Genomics to sequence 100 genomes for multiple family studies of Huntington's and other diseases in collaboration with several academic institutions. These studies have demonstrated even lower error rates than the data generated in 2009.

"Over the past two years, Complete Genomics has played a critical role in our investigation of several diseases in multigenerational families. Its proven complete human genome sequencing service has helped our scientists in these detailed genetic analyses. The Miller syndrome study by ISB, the University of Utah and the University of Washington, was groundbreaking," said ISB Senior Vice President for Strategic Partnerships David Galas.

"Partnering with Complete Genomics for our human sequencing needs has allowed us to focus on data analysis and interpretation while avoiding major capital expense, pipeline building and technology development. Their continuous increase in sequencing accuracy and coverage has allowed us to generate highly accurate results," said ISB President Dr. Leroy Hood. All of the work at ISB on these projects has been supported by the partnership between ISB and the University of Luxembourg, in particular with the Luxembourg Centre for Systems Biomedicine.

Neurodegenerative diseases cover a broad range of disorders that affect neurons, or neuromuscular control, many of which are genetic or hereditary in nature, such as Huntington's disease. For this study, ISB will, in coordination with its academic partners, supply the purified DNA samples from families with multiple affected individuals. Complete Genomics will perform the sequencing, assembly and annotation and deliver to ISB a listing of variations found in each genome. ISB will then do its own further analysis, utilizing the power of family genetics and network analysis with the data sets to identify causal and modifying genes.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs